Abstract
Electronic cigarette (e-cigarette) use or ‘vaping’ has stormed the world over the past years. It is available everywhere and regardless of age, and is aggressively marketed as a safe way to stop smoking despite a lack of solid evidence. Reality is that we do not know the consequences of vaping on pulmonary health and research is urgently needed to identify potential health hazards.
While most emphasis is placed on nicotine and flavouring agents found in e-liquid, very little scientific knowledge is available on the acute effects of propylene glycol and glycerol inhalation, the two compounds representing the great majority of e-liquid total volume. We therefore aimed at characterizing the acute effects of inhaling propylene glycol and glycerol on lung functions. We were also interested to compare potential differences between volunteers with no documented lung disease and volunteers with diagnosed asthma, as the latter are generally more sensitive to pulmonary irritants and bronchoconstrictive stimuli.
We conducted a randomized cross-over, placebo-controlled study on the acute effect of nicotine-free and flavour-free e-cigarette vapor inhalation. Volunteers were aware of using full (experimental) or empty (placebo) e-cigarettes as no vapors were coming out of the empty placebo device. The e-liquid consisted of a mixture of 70% USP-grade propylene glycol (PG) and 30% USP-grade glycerol (Gly), mixed in our laboratory under a biosafety cabinet. This 70%PG/30%Gly mixture is largely representative of what is used on the market to dissolve nicotine and/or flavours. Our approach was to create the best-case scenario, where unwanted and possibly harmful contaminants are absent, to specifically investigate the pulmonary effects of PG and Gly. Twenty healthy volunteers and ten asthmatic volunteers were recruited for the trial. Healthy volunteers were aged between 20 and 37 years, had no documented lung disease and had normal response to methacholine. Asthmatic volunteers were aged between 21 and 40 years and all had received a diagnosis of asthma and had airway hyperresponsiveness as shown by a positive methacholine challenge. All volunteers were non-smokers and none were active e-cigarette users. Moreover, none of the volunteers were exposed to secondary tobacco or e-cigarette vapors at home. All volunteers gave their written informed consent and the IUCPQ-UL Ethics Board approved the trial (reference number 2015–2459 21256).
The experimental and placebo sessions took place 1 week apart. A preceding visit was also planned, where baseline measurements were taken (i.e. vital signs, lung functions, airway resistance measurements), a methacholine challenge was performed according to Juniper et al. [1], and volunteers were familiarized with the e-cigarette. On the following two sessions (experimental and placebo), volunteers were asked to inhale three times per minute, in sitting position, for a total duration of 1 hour. Respiratory mechanics and lung functions were measured by the forced oscillation technique (TremoFlow) and spirometry, respectively and in that order, immediately before (T0), immediately after (T60), and 30 min after (T90) the inhalation sessions. Respiratory symptoms were collected according to the Borg perception scale at the same time points as well as every 20 min during the inhalation session. The fraction of exhaled nitric oxide (FeNO) and serum C-reactive protein (CRP) were also measured in asthmatic volunteers. FeNO and serum samples were not collected in non-asthmatic volunteers.
All volunteers were able to complete the sessions. Data collected are presented in Table 1. A few subjects noticed symptoms when using the loaded e-cigarette including cough, chest tightness, and secretions, but no consensual differences in symptoms were noticed in healthy or asthmatic volunteers. Changes in vital signs such as oxygen saturation, heart rate, and breathing frequency were not different between placebo or experimental sessions. No changes in lung functions were observed using either spirometry or forced oscillation technique. Finally, signs of flaring inflammation, such as increased FeNO and serum CRP levels, were not observed in response to e-cigarette in the asthmatic group.
